SCHEMBL19002182

SCHEMBL19002182

CC(C)(C)c1ccc(C(=O)SNC(=O)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK9 Q9NPC2 1/20 0.55
RAB9A P51151 5/20 0.53
LMNA P02545 1/20 0.53
HDAC1 Q13547 1/20 0.51
NPC1 O15118 3/20 0.50
ESRRG P62508 2/20 0.50
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
GLA P06280 1/20 0.48
ATM Q13315 1/20 0.48
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NR1H4 Q96RI1 3/20 0.47
POLB P06746 2/20 0.47
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SRD5A2 P31213 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11570198 0.88 HDAC3 (0.50) KCNK9RAB9ALMNAHDAC1NPC1
SCHEMBL9274738 0.86 ALOX15 (0.52) KCNK9RAB9AHDAC1NPC1ALDH1A1
SCHEMBL9915150 0.84 NPC1 (0.57) RAB9ALMNANPC1MAPTCASP3
SCHEMBL9915156 0.83 POLB (0.57) RAB9ALMNAHDAC1NPC1ALDH1A1
SCHEMBL15281686 0.80 NPC1 (0.54) KCNK9RAB9ALMNANPC1ALDH1A1
SCHEMBL9915113 0.80 NPC1 (0.54) KCNK9RAB9ALMNANPC1ALDH1A1
SCHEMBL21326406 0.80 KMT2A (0.49) RAB9ALMNAHDAC1NPC1ALDH1A1
SCHEMBL9915153 0.79 NPC1 (0.58) KCNK9RAB9ANPC1ALDH1A1KMT2A
SCHEMBL15281773 0.79 RAB9A (0.57) RAB9ALMNAHDAC1NPC1ALDH1A1
SCHEMBL9915085 0.76 NPC1 (0.46) KCNK9RAB9ALMNAHDAC1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023142996-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT 上海岸阔医药科技有限公司 2023-08-03 WO disclosed
US-10450260-B2 NO- and H2S-releasing compounds RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2019-10-22 US disclosed
US-10023555-B2 NSAIDs derivatives and uses thereof RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2018-07-17 US disclosed
US-20170260124-A1 NO- AND H2S- RELEASING COMPOUNDS RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK 2017-09-14 US disclosed
US-9688607-B2 No- and H2S-releasing compounds RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2017-06-27 US disclosed
US-20170174651-A1 Method of Priming Plants Against Abiotic Stress Factors CYPRUS UNIVERSITY OF TECHNOLOGY (CY) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260124-A1 NO- AND H2S- RELEASING COMPOUNDS NOS2, NOS3, NOS1 KCNK9 3485/4885RAB9A 2332/4885LMNA 4773/4885
US-10450260-B2 NO- and H2S-releasing compounds NOS2, NOS3, NOS1 KCNK9 3485/4885RAB9A 2332/4885LMNA 4773/4885
US-10023555-B2 NSAIDs derivatives and uses thereof PTGES, PTGES3, PTGS1 KCNK9 2159/4885RAB9A 3622/4885LMNA 3842/4885
US-20170174651-A1 Method of Priming Plants Against Abiotic Stress Factors NOS2, NOS1, HSF1 KCNK9 4160/4885RAB9A 3554/4885LMNA 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.